Optaflu

From Wikipedia, the free encyclopedia
Jump to: navigation, search

Optaflu is a cell culture derived influenza vaccine manufactured by Novartis.

History[edit]

On April 27, 2007 Novartis received a positive opinion supporting European Union approval of Optaflu. It is the first influenza vaccine made in a mammalian cell line, rather than chicken eggs.[1] The vaccine will be manufactured in Holly Springs, North Carolina. The United States government is providing $500 million in construction costs and guaranteed vaccine purchases.[2]

References[edit]

  1. ^ "Optaflu, the Novartis cell culture-derived influenza vaccine, receives positive opinion supporting European Union regulatory approval". Novartis. Retrieved 2009-04-29. 
  2. ^ Pollack, Andrew (2009). "Swine Flu Vaccine May Be Months Away, Experts Say". New York Times. Retrieved 2009-04-29. "But Novartis is building a cell culture flu vaccine factory in Holly Springs, N.C., which might be ready for use in 2010 or 2011. The federal government is providing nearly $500 million in construction costs and guaranteed vaccine purchases."